Free Webinar: Accessing China’s GBA via Hong Kong Listing - Essential Information for Life Sciences Companies
For life sciences companies seeking a practical route into China’s Greater Bay Area, this webinar explains how a Hong Kong listing can support market access, hospital adoption, and long-term China commercialization strategy.
In this session, Hamish King and Jacky Li from Cisema present the regulatory and commercial fundamentals behind the GBA expedited pathway, with a focus on medical devices, IVDs, and pharmaceutical products. The discussion covers how companies can use Hong Kong medical device listing or Hong Kong drug registration as a stepping stone toward Greater Bay Area market entry, early revenue opportunities, and potential support for future China-wide NMPA approval.
Drawing on Cisema’s regulatory, quality, clinical, and market entry experience, the webinar gives international manufacturers a clearer view of how the Hong Kong-GBA pathway works in practice, what regulators and hospitals are looking for, and how to position products for success.
Watch the Webinar
What You’ll Learn
- How the Hong Kong listing pathway can support faster entry into China’s Greater Bay Area for life sciences companies
- What companies need to know about GBA eligibility, hospital-driven approvals, and regulatory requirements for medical devices, IVDs, and drugs
- How a Hong Kong-first strategy can help build early market access, revenue, and evidence for broader China commercialization
Who Should Watch
This webinar is relevant for:
- Medical device, IVD, pharmaceutical, and biotech companies
- Regulatory affairs, market access, and commercialization teams
- Business development leaders evaluating Hong Kong listing, GBA market entry, or future NMPA approval
Event Details
- Event Title: Accessing China’s GBA via Hong Kong Listing: Essential Information for Life Sciences Companies
- Duration: Approximately 30 minutes
- Topic Areas: China regulatory strategy, Hong Kong listing, GBA expedited pathway, medical devices, IVDs, pharmaceuticals, market entry
- Langauge: English
Meet the Speakers
Hamish King
CEO, Cisema
Hamish King is CEO at Cisema and a lawyer by training, qualified in New South Wales, Australia, and Hong Kong. Based in Hong Kong for the past eight years, he advises international companies on regulatory strategy, market entry, and compliance across China and the Asia-Pacific region.
Jacky Li
Senior Manager, Cisema
Jacky Li has been with Cisema for more than five years and leads support for Hong Kong medical device listing and drug registration projects, helping companies navigate regulatory requirements and commercialization pathways for the Hong Kong and Greater Bay Area markets.
Ready to Explore Your Hong Kong and GBA Market Entry Strategy?
Contact Cisema to discuss Hong Kong listing, drug registration, GBA pathway eligibility, and China regulatory planning.